Page 5 - Randomized Evaluation News Today

This multicenter randomized clinical trial compares the effects of 12 mg/d vs 6 mg/d of dexamethasone in patients with COVID-19 and severe hypoxemia.

This study compares the effect of convalescent plasma vs no convalescent plasma on the outcome of organ support–free days in the hospital among critically ill a

Regeneron mAb cocktail benefits hospitalized patients with no natural SARS-CoV-2 antibody response Researchers reporting on findings from the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial in the UK are recommending that any therapeutic use of REGEN-COV may be best restricted to individuals without detectable antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The RECVORY Collaborative Group says that among patients hospitalized with coronavirus disease ...

COVID-19: why critically ill patients in Africa are taking a bigger hit The Conversation 22 May 2021, 20:43 GMT+10 In March 2020, those of us living on the African continent were terrified about what would happen. We had watched Wuhan and then Italy get overrun by Covid-19. These were environments far more resourced than Africa . We knew that we had a limited healthcare workforce. And we have estimated that there was about one critical care bed per 100 000 population on the continent. The avera...

Columbia Universitys Mailman School of Public Health A randomized double-blind controlled trial of convalescent plasma for adults hospitalized with severe COVID-19 found that mortality at 28 days in the treatment arm was half the rate seen in the control arm (12.6% vs. 24.6%), although treatment was not associated with other improvements in clinical status. The study was led by investigators from the Center for Infection and Immunity at Columbia University Mailman School of Public Health; Colum...

sudok1 / iStock A systematic review and meta-analysis of 10 randomized controlled studies concludes that use of convalescent plasma in COVID-19 patients doesnt appear to improve survival or clinical status, shorten hospital stays, or reduce the need for mechanical ventilation. Led by researchers at the University of Basel in Switzerland and published late last week in JAMA, the study found that the risk ratio (RR) for death in the four peer-reviewed, published trials involving 1,060 coronaviru...

Three of the trials did not have study acronyms (only trial registration numbers) and ILBS-COVID-02 and PLACID did not have expansions in the original publications. ConCOVID indicates Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease; ConPlas-19, Convalescent Plasma Therapy vs SOC for the Treatment of COVID-19 in Hospitalized Patients; NA, not available; PICP19, Passive Immunization With Convalescent Plasma in Severe COVID-19 Disease; PlasmAr, Convalescent Plasma and Placebo...

Perrine Janiaud, PhD; Cathrine Axfors, MD, PhD; Andreas M. Schmitt, MD; Viktoria Gloy, PhD; Fahim Ebrahimi, MD, MSc; Matthias Hepprich, MD; Emily R. Smith, ScD, MPH; Noah A. Haber, ScD; Nina Khanna, MD; David Moher, PhD; Steven N. Goodman, MD, PhD; John P. A. Ioannidis, MD, DSc; Lars G. Hemkens, MD, MPH In this issue of JAMA, Janiaud et al 1 present a meta-analysis of randomized clinical trials (RCTs) of convalescent plasma for the treatment of patients with COVID-19....

A To assess the safety and effectiveness of their Covid-19 vaccines, BioNTech SE, Pfizer Inc. and Moderna Inc. sponsored clinical trials overseen by independent boards that recruited tens of thousands of participants, randomly assigned them to receive vaccines or placebos and waited to see if there was a discernible difference in outcomes between the two groups. With the rapid spread of the new coronavirus in the US this fall, they didn’t have to wait long — and the results were stunni...